TY - JOUR
T1 - A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials
AU - PRECEDENT Study Group
AU - Potter, Shelley
AU - Avery, Kerry
AU - Ahmed, Rosina
AU - de Boniface, Jana
AU - Chatterjee, Sanjoy
AU - Dodwell, David
AU - Dubsky, Peter
AU - Federmann, Jingjing
AU - Finestone, Sandra
AU - Gnant, Michael
AU - Hlauschek, Dominik
AU - Iwata, Hiroji
AU - Jiang, Michael Y.
AU - Kaidar-Person, Orit
AU - Lee, Han Byoel
AU - MacKenzie, Mairead
AU - Meyn, Anne
AU - Poortmans, Philip
AU - Poulakaki, Fiorita
AU - Richardson, Andrea L.
AU - Sepulveda, Karla A.
AU - Spillane, Andrew J.
AU - Thompson, Alastair M.
AU - Werutsky, Gustavo
AU - Wittmann, Philipp
AU - Wright, Jean L.
AU - Zdenkowski, Nicholas
AU - Cowan, Katherine
AU - McIntosh, Stuart A.
AU - Zope, Anagha
AU - Zivkovic, Marija
AU - Zeko, Amanda
AU - Cobos, Gastón Zatta
AU - Žatecký, Jan
AU - Youn, Hyun Jo
AU - Yiallourou, Anneza
AU - Yeh, Janice
AU - Kumar, Sanjay
AU - Wyld, Lynda
AU - Wong, Stephanie
AU - Wiebe, Ericka
AU - Warnberg, Fredrik
AU - Wapnir, Irene
AU - Walker, Melanie
AU - Wadasadawala, Tabassum
AU - Voutsadakis, Ioannis
AU - Vohra, Lubna
AU - Vidal-Sicart, Sergi
AU - Venkitaraman, Ramachandran
AU - Gomez, Henry Leonidas
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Accurate information about locoregional breast cancer treatments following neoadjuvant systemic therapy (NST) is essential for meaningful interpretation of oncological outcomes but reporting is currently poor. We developed a core outcome set (COS) to improve the quality and consistency of locoregional outcome reporting in breast cancer NST trials. The COS was developed in three phases according to COS-STAD guidance, with the generation of a list of relevant outcome domains, prioritisation of outcomes through two rounds of an international online multi-stakeholder Delphi survey and a consensus meeting. 159 unique locoregional outcomes were classified into 101 outcome domains for inclusion in the Delphi survey, which was completed by 470 international professionals. The final 15-item COS, which included the pre-NST surgical plan, details of surgery performed following completion of treatment and details of radiation therapy, was agreed at an in-person consensus meeting. Widespread COS implementation will improve the quality and value of future NST trials.
AB - Accurate information about locoregional breast cancer treatments following neoadjuvant systemic therapy (NST) is essential for meaningful interpretation of oncological outcomes but reporting is currently poor. We developed a core outcome set (COS) to improve the quality and consistency of locoregional outcome reporting in breast cancer NST trials. The COS was developed in three phases according to COS-STAD guidance, with the generation of a list of relevant outcome domains, prioritisation of outcomes through two rounds of an international online multi-stakeholder Delphi survey and a consensus meeting. 159 unique locoregional outcomes were classified into 101 outcome domains for inclusion in the Delphi survey, which was completed by 470 international professionals. The final 15-item COS, which included the pre-NST surgical plan, details of surgery performed following completion of treatment and details of radiation therapy, was agreed at an in-person consensus meeting. Widespread COS implementation will improve the quality and value of future NST trials.
UR - https://www.scopus.com/pages/publications/105035365138
U2 - 10.1038/s41523-025-00824-w
DO - 10.1038/s41523-025-00824-w
M3 - Artículo
AN - SCOPUS:105035365138
SN - 2374-4677
VL - 11
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 116
ER -